Chengdu Kangnuoxing Biopharma,inc.
Clinical trials sponsored by Chengdu Kangnuoxing Biopharma,inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot for teen hay fever? early trial underway Results expected Oct 2026 (estimated)
- New injection could tame teen hay fever Results expected Dec 2026 (estimated)
-
New shot for eczema shows promise in large trial
Disease control Recruiting nowThis study is testing a new biologic drug called Stapokibart, given as a shot, for adults with moderate-to-severe atopic dermatitis (eczema). The trial will enroll 1000 people to see if the drug is safe and helps control the condition. It is an open-label study, meaning everyone …
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New injection could tame teen hay fever
Symptom relief Recruiting nowThis study tests whether an injection called stapokibart can reduce nasal allergy symptoms like runny nose, congestion, sneezing, and itching in adolescents aged 12 to 17 with seasonal allergic rhinitis (hay fever). Participants receive either stapokibart or a placebo alongside t…
Phase 3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC